As small molecule drugs, one of the hurdles in molecular glue advancement is their progression into clinical therapeutics. Although some progress in understanding their mechanisms of action has been achieved, the pharmacokinetic and pharmacodynamic profiles of newly developed molecular glues are still largely unknown, which obstructs their further development into drug candidates. Comprehensive studies into the detailed pathways of the pathogenic protein degradation via the ubiquitin-proteasome system enabled by each specific molecular glue is of key importance for their optimization and perfection into successful drugs. Despite these hurdles, molecular glue companies and research organizations are taking on the challenge to progress discovered molecular glues not only to the clinic but ultimately to market. From established companies and research organizations to 2022 start-up companies, they all have the same mission to treat diseases with high unmet needs and transform how disease treatment is approached.